The Australian pharmaceutical company, MGC Pharmaceuticals, has entered the American cosmetics market by receiving an approval from Food and Drug Administration (FDA) for its MGC derma products that are manufactured from medical cannabis. This approval will enable MGC to market and distribute this line of products throughout USA. MGC will be able to import and sell its 16 derma products, even in states where cannabis is not yet legal. This approval was followed by MGC being granted permission to sell and distribute its cosmetic products throughout the EU with an approval from the European Commission’s Cosmetic Products Notification Portal (CPNP). This has given a great boost to the company to penetrate the American and European markets. MGC has applications pending for similar regulatory approvals in Canada and Australia, where it hopes to achieve supremacy.